Teresiah Kanyingi
Adult Health · Camden, DENPI 1902372105
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 38 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Novo Nordisk at 28.9% of the total. Reporting peaked in 2024 at $323 and has fallen 77.0% since, to $74 in 2025.
Across 38 payments — averaging $17.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$194
- Amgen$63
- Sumitomo Pharma America, Inc.$59
- Amarin Pharma, Inc.$48
- Idorsia Pharmaceuticals US Inc$45
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$41
- plus $223 from 10 others
What the payments were for
- Food & beverage$672100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 12 | $194 |
| Amgen | 3 | $63 |
| Sumitomo Pharma America, Inc. | 3 | $59 |
| Amarin Pharma, Inc. | 2 | $48 |
| Idorsia Pharmaceuticals US Inc | 3 | $45 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $41 |
| Sanofi-aventis U.S. LLC | 2 | $40 |
| E.r. Squibb & Sons, L.L.C. | 2 | $37 |
| Lilly USA, LLC | 2 | $26 |
| Johnson & Johnson | 1 | $21 |
| Astellas Pharma US Inc | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Exact Sciences | 1 | $17 |
| AbbVie | 1 | $16 |
| Merck | 1 | $15 |
| AstraZeneca | 1 | $13 |
How this compares
$672 in reported general payments places this provider in the 65th percentile of 65 adult health providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 38 | $45,487 |
| EliquisApixaban | 24 | $24,523 |
| TrulicityDulaglutide | 11 | $19,884 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 13 | $5,755 |
| Novolin 70-30Insulin Nph Hum/Reg Insulin Hm | 11 | $2,563 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 94 | $2,122 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $2,067 |
| Gabapentin | 96 | $1,571 |
| PaxlovidNirmatrelvir/Ritonavir | 17 | $1,429 |
| Omeprazole | 68 | $1,221 |
| Fluticasone Propionate | 96 | $1,211 |
| Diclofenac Sodium | 40 | $1,125 |
| Atorvastatin Calcium | 132 | $1,068 |
| Amlodipine Besylate | 196 | $1,058 |
| Levothyroxine Sodium | 59 | $1,043 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $194 | $45,48738 claims |
| Lilly USA, LLCTrulicity | $26 | $19,88411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 65 adult health providers in Delaware.
Other adult health in Camden
- Emily KellerWilmington$26K
- Mayumi Lea AnthonyNewark$16K
- Mary HighWilmington$8K
- Andrea ForsythNewark$3K
- Janice James-WebbLaurel$3K
- Leslie VerucciNewark$3K
- Adrienne WoodsWilmington$2K
- Rhonda DavisMillsboro$2K
- Dannette MitchellWilmington$2K
- Kathe Hefner-EricksonNewark$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.